181 related articles for article (PubMed ID: 38190383)
21. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
[TBL] [Abstract][Full Text] [Related]
22. An update on primary sclerosing cholangitis:from pathogenesis to treatment.
Imam MH; Talwalkar JA; Lindor KD
Minerva Gastroenterol Dietol; 2013 Mar; 59(1):49-58. PubMed ID: 23478243
[TBL] [Abstract][Full Text] [Related]
23. Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Hegade VS; Jones DE; Hirschfield GM
Dig Dis; 2017; 35(3):267-274. PubMed ID: 28249258
[TBL] [Abstract][Full Text] [Related]
24. Current Targets for Primary Sclerosing Cholangitis.
Pierantonelli I; Benedetti A; Marzioni M
Curr Drug Targets; 2017; 18(8):901-907. PubMed ID: 26758666
[TBL] [Abstract][Full Text] [Related]
25. Bile acids for primary sclerosing cholangitis.
Poropat G; Giljaca V; Stimac D; Gluud C
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655
[TBL] [Abstract][Full Text] [Related]
26. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
27. Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans.
Arenas-Gamboa AM; Bearss JJ; Hubbard GB; Porter BF; Owston MA; Dick EJ
Vet Pathol; 2012 May; 49(3):524-7. PubMed ID: 21934101
[TBL] [Abstract][Full Text] [Related]
28. Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis.
Rothweiler S; Feldbrügge L; Jiang ZG; Csizmadia E; Longhi MS; Vaid K; Enjyoji K; Popov YV; Robson SC
Purinergic Signal; 2019 Sep; 15(3):375-385. PubMed ID: 31243614
[TBL] [Abstract][Full Text] [Related]
29. Characterization of animal models for primary sclerosing cholangitis (PSC).
Fickert P; Pollheimer MJ; Beuers U; Lackner C; Hirschfield G; Housset C; Keitel V; Schramm C; Marschall HU; Karlsen TH; Melum E; Kaser A; Eksteen B; Strazzabosco M; Manns M; Trauner M;
J Hepatol; 2014 Jun; 60(6):1290-303. PubMed ID: 24560657
[TBL] [Abstract][Full Text] [Related]
30. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.
van Milligen de Wit AW; van Deventer SJ; Tytgat GN
Am J Gastroenterol; 1995 Jun; 90(6):893-900. PubMed ID: 7771416
[TBL] [Abstract][Full Text] [Related]
31. Primary sclerosing cholangitis: diagnosis, prognosis, and management.
Singh S; Talwalkar JA
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):898-907. PubMed ID: 23454027
[TBL] [Abstract][Full Text] [Related]
32. Sclerosing cholangitis: pediatric perspective.
Kerkar N; Miloh T
Curr Gastroenterol Rep; 2010 Jun; 12(3):195-202. PubMed ID: 20425475
[TBL] [Abstract][Full Text] [Related]
33. Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.
Fejfar T; Vaňásek T; Hůlek P
Vnitr Lek; 2020; 66(5):287-300. PubMed ID: 32942866
[TBL] [Abstract][Full Text] [Related]
34. Primary sclerosing cholangitis.
Mendes FD; Lindor KD
Clin Liver Dis; 2004 Feb; 8(1):195-211. PubMed ID: 15062201
[TBL] [Abstract][Full Text] [Related]
35. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis.
Nielsen MJ; Thorburn D; Leeming DJ; Hov JR; Nygård S; Moum B; Saffioti F; Gilja OH; Boberg KM; Mazza G; Røsjø H; Pinzani M; Karlsen TH; Karsdal MA; Vesterhus M
Aliment Pharmacol Ther; 2018 Jul; 48(2):179-189. PubMed ID: 29851098
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and outcome of primary sclerosing cholangitis associated with inflammatory bowel disease in Asian children.
Lee WS; Karthik SV; Ng RT; Ong SY; Ong C; Chiou FK; Wong SY; Quak SH; Aw MM
Pediatr Neonatol; 2019 Aug; 60(4):396-404. PubMed ID: 31409456
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.
Saffioti F; Gurusamy KS; Hawkins N; Toon CD; Tsochatzis E; Davidson BR; Thorburn D
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011343. PubMed ID: 28417463
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation profile of liver tissue in end-stage cholestatic liver disease.
Cheung AC; Juran BD; Schlicht EM; McCauley BM; Atkinson EJ; Moore R; Heimbach JK; Watt KD; Wu TT; LaRusso NF; Gores GJ; Sun Z; Lazaridis KN
Epigenomics; 2022 Apr; 14(8):481-497. PubMed ID: 35473391
[TBL] [Abstract][Full Text] [Related]
39. Histological and immunohistochemical study of the gall bladder lesion in primary sclerosing cholangitis.
Jeffrey GP; Reed WD; Carrello S; Shilkin KB
Gut; 1991 Apr; 32(4):424-9. PubMed ID: 2026342
[TBL] [Abstract][Full Text] [Related]
40. Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.
Sedki M; Levy C
Curr Gastroenterol Rep; 2018 Jun; 20(7):29. PubMed ID: 29886518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
